VEGF Signaling Pathways in Glioblastoma: Is the Evidence Sufficient for Widespread Use? A European Perspective
First uncontrolled trials suggest significant activity of bevacizumab in recurrent glioblastoma. However, many questions still remain unresolved, in particular in view of the occurrence of pseudo-responses, the development of gliomatosis cerebri, the unclear impact on survival, and the high costs associated with this treatment. Further studies need to focus the early identification of responders, better combination regimen, and on the assessment of survival benefit. The widespread use of bevacizumab prior to registration may actually become an obstacle for the answering of some of these questions.